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ABVD

:   doxorubicin, bleomycin, vinblastine, dacarbazine

AC

:   doxorubicin, cyclophosphamide

ALL

:   acute lymphoblastic leukemia

AMH

:   anti-Müllerian hormone

AML

:   acute myeloid leukemia

ART

:   assisted reproductive technologies

BEACOPP

:   bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone

BOT

:   borderline tumor

CAF

:   cyclophosphamide, adriamycin, fluorouracil

CEF

:   cyclophosphamide, epirubicin, 5-flourouracil

ChlVPP/EVA hybrid COPP

:   chlorambucil, vinblastine, procarbazine, prednisone/ etoposide, vincristine, doxorubicin

CHOP

:   cyclophosphamide, doxorubicin, vincristine, prednisolone

CI

:   confidence interval

CMF

:   cyclophosphamide, methotrexate, 5-fluorouracil

CML

:   chronic myelogenous leukemia

CVP

:   cyclophosphamide, vincristine, prednisone

DMSO

:   dimethyl sulfoxide

EC

:   epirubicin, cyclophosphamide

ESD

:   effective sterilizing dose

FOLFOX

:   folinic acid (leucovorin), 5-fluorouracil, oxaliplatin

GnRH

:   gonadotropin-releasing hormone

GnRHa

:   gonadotropin-releasing hormone agonist

Gy

:   Gray

HL

:   Hodgkinʼs lymphoma

MVPP

:   mustine, vinblastine, procarbazine, prednisolone

NHL

:   non-Hodgkinʼs lymphoma

OR

:   odds ratio

POI

:   premature ovarian insufficiency

RR

:   relative risk

SCT

:   stem cell transplantation

TAC

:   paclitaxel (taxol), doxorubicin (adriamycin), cyclophosphamide

TKI

:   tyrosine kinase inhibitors  

II  Guideline Application
=========================

Purpose and Objectives
----------------------

The purpose of this guideline is to provide recommendations for action with regard to counseling and fertility preservation for prepubertal girls and women of reproductive age with oncologic disease which take account of the patientsʼ personal circumstances and risk profile. The aim is to increase the rate of successful pregnancies after completing oncologic therapy and to improve the patientsʼ quality of life.

Targeted areas of patient care
------------------------------

-   Outpatient care

-   Inpatient care

-   Semi-residential care

Target patient groups
---------------------

The guideline is aimed at all prepubertal girls and patients of reproductive age who require gonadotoxic treatment for malignant disease.

Target user group/target audience
---------------------------------

This guideline is aimed at all physicians and medical professionals involved in the care of patients who require gonadotoxic therapy.

The principal among these are: gynecologists, reproductive medicine physicians, andrologists, urologists, oncologists, radio-oncologists, general practitioners, pediatricians, pathologists, psycho-oncologists.

Adoption of the guideline and period of validity
------------------------------------------------

This guideline is valid from November 1, 2017 to October 31, 2020. Because of the contents of the guideline, this period of validity is only an estimate. If there are important changes to the evidence, then amendments to the guideline will be published before the period of validity has expired, once the new evidence has been carefully reviewed in accordance with the methodology of the AWMF.

III  Methodology
================

Basic principles
----------------

The methodology used to prepare this guideline is determined by the class to which the guideline is assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and regulations for the classification of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a summary of recommendations for action compiled by a non-representative group of experts. In 2004 the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches.

This guideline is classified as: S2k

Grading of recommendations
--------------------------

While the description of the quality of the evidence (strength of evidence) serves as an indication for the robustness of the publicized data and therefore expresses the extent of certainty/uncertainty about the data, the classification of the level of recommendation reflects the result of weighing up the desirable and adverse consequences of alternative approaches.

A grading of the evidence and of the recommendations is not envisaged for S2k-level guidelines. The level of recommendation is differentiated by syntax, not by symbols. The syntax used to grade the level of recommendation is described in the background text ( [Table 2](#TB6115549-2){ref-type="table"} ).

###### 

**Table 2**  Grading of recommendations.

  Description of level of recommendation   Syntax
  ---------------------------------------- -------------------
  Strong recommendation, highly binding    must/must not
  Recommendation, moderately binding       should/should not
  Open recommendation, not binding         may/may not

Statements
----------

Expert statements included in this guideline which are not recommendations for action but simple statements of fact are referred to as Statements. It is not possible to provide a level of evidence for these statements.

Achieving consensus and strength of consensus
---------------------------------------------

As part of structured consensus-based decision-making (S2k/S3 level), authorized participants present at consensus sessions vote on draft Statements and Recommendations. Discussions at the sessions can lead to significant changes in the wording of Statements and Recommendations. The extent of agreement, which depends on the number of participants, is then determined at the end of the session ( [Table 3](#TB6115549-3){ref-type="table"} ).

###### 

**Table 3**  Classification on extent of agreement following consensus-based decision-making.

  Symbol   Strength of consensus   Extent of agreement in percent
  -------- ----------------------- ------------------------------------
  +++      Strong consensus        \> 95% of participants agree
  ++       Consensus               \> 75 -- 95% of participants agree
  \+       Majority agreement      \> 50 -- 75% of participants agree
  --       No consensus            \< 50% of participants agree

Expert consensus
----------------

As the name implies, this term refers to consensus decisions taken with regard to specific Recommendations/Statements without a previous systematic search of the literature (S2k) or when evidence is lacking (S2e/S3). The term "expert consensus" (EC) used here is synonymous with terms used in other guidelines such as "good clinical practice" (GCP) or "clinical consensus point" (CCP). The strength of the recommendation is graded as previously described in the chapter "Grading of recommendations"; the strength of consensus is only indicated semantically ("must"/"must not" or "should"/"should not" or "may"/"may not") with no use of symbols.

IV  Guideline
=============

Statements and Recommendations on fertility preservation for girls and women with oncologic disease are presented below.

1  Introduction to Fertility Protection for Persons Diagnosed with Oncologic Disease
------------------------------------------------------------------------------------

### 1.2  Importance and problems of fertility protection for persons diagnosed with cancer

Oncologic therapies often lead to partial or complete impairment of gonadal function in both men and women along with the potential loss of germ cells. Faced by the impact of a life-threatening disease, subsequent infertility may appear to be a minor issue for non-affected persons. For many of the patients themselves, however, premature ovarian insufficiency or sterility is a very stressful situation for both the affected patient and their partner [@R6115549-2] ,  [@R6115549-3] .

  Consensus-based Recommendation 1.R1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Assessing the risk of possible infertility and the choice of method(s) for fertility preservation must be done by an interdisciplinary panel and discussed with the patient in good time before the start of oncologic therapy.

  Consensus-based Statement 1.S1
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Counseling about concepts to preserve fertility must be an integral part of every patientʼs oncologic treatment and must take account of the patientʼs personal circumstances, recommended oncologic therapy and individual risk profile.

2  Causes of Gonadal Toxicity in Women
--------------------------------------

### 2.1  Gonadal damage from surgery

Depending on the extent of radical surgery, gynecologic oncologic disease can result in sterility following complete or partial removal of the uterus and/or ovaries. Fertility-preserving surgery for various tumor entities is discussed in Chapter 4.1 of the long version of the guideline.

### 2.2  Gonadal toxicity from chemotherapy

The gonadal toxicity of individual chemotherapeutic drugs depends on their mechanism of action, the administered dose, the duration of therapy, the way in which therapy is administered, concomitant therapeutic treatments such as simultaneous radiotherapy or ovary-removal surgery, the patientʼs age, and the patientʼs individual disposition ( [Table 4](#TB6115549-4){ref-type="table"} ).

###### 

**Table 4**  Ovarian toxicity of different chemotherapeutic drugs (modified from [@R6115549-4] ,  [@R6115549-5] ).

  Risk                                                         Regimen/Substance
  ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  High risk (\> 80% risk of permanent amenorrhea)              CMF, CEF, CAF, TAC × 6 for women aged ≥ 40 yearsConditioning for stem cell transplantation (particularly alkylating agent-based myeloablative conditioning with busulfan, cyclophosphamide, melphalan)BEACOPP × 6 -- 8 for women aged \> 35 years
  Intermediate risk (40 -- 60% risk of permanent amenorrhea)   CMF, CEF, CAF, TAC × 6 for women aged 30 -- 39 yearsAC × 4 for women aged ≥ 40 yearsAC or EC × 4 → taxaneBEACOPP × 6 -- 8 for women aged 25 -- 35 yearsCHOP × 6 for women aged ≥ 35 yearsStandard therapies for bone and soft tissue sarcomas
  Low risk (\< 20% risk of permanent amenorrhea)               CMF, CEF, CAF, TAC × 6 for women aged ≤ 30 yearsAC × 4 for women aged ≤ 40 yearsBEACOPP × 6 -- 8 for women aged \< 25 yearsABVD × 2 -- 4CHOP × 6 for women aged \< 35 yearsCVPAML-type therapy (anthracyclines/ cytarabine)ALL-type therapy (multi-agent)FOLFOX for women aged ≤ 40 years
  Very low or no risk of permanent amenorrhea                  MethotrexateFluorouracilVincristine

  Consensus-based Statement 2.R2
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Women scheduled to receive a potentially gonadotoxic dose of chemotherapeutic drugs must be informed about the risk of ovarian insufficiency and about methods to preserve fertility.

  Consensus-based Statement 2.S3
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The negative impact of the gonadal toxicity of chemotherapies increases with patient age. Not all patients in a specific age group who receive therapy according to a defined regimen will develop the same fertility disorder.

### 2.3  Gonadal toxicity from radiotherapy

#### 2.3.1  Ovarian radiation damage

( [Table 5](#TB6115549-5){ref-type="table"} )

###### 

**Table 5**  Radiotoxicity and ovarian insufficiency (modified from [@R6115549-6] ).

  Effective sterilizing dose (ESD)    Ovarian radiation dose (Gy)
  ----------------------------------- -----------------------------
  No relevant effect                  0.6
  No relevant effect at \< 40 years   1.5
  0 years                             20.3
  10 years                            18.4
  20 years                            16.5
  30 years                            14.3
  40 years                            6

  Consensus-based Statement 2.S4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Whether women develop ovarian insufficiency depends on the radiation dose, the age when the patient was exposed to radiation and the volume of irradiated ovarian tissue.

  Consensus-based Recommendation 2.R3
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients who are scheduled to receive radiotherapy which will also irradiate the anatomical area of the ovaries must be informed about the risk of ovarian damage and must be made aware of methods which could preserve their fertility.

#### 2.3.2  Tubal radiation damage

Radiogenic tubal changes can lead to a loss of function, resulting in limited fertility. Extrauterine pregnancies and their associated subsequent complications can occur, even if ovarian and uterine function have been preserved. Nothing is known about tubal tolerance doses.

#### 2.3.3  Uterine radiation damage

In contrast to chemotherapy, radiotherapy can affect uterine function in addition to affecting the ovaries. Here again, the effect depends on the dose; the dose-response relationship has not yet been clearly defined [@R6115549-7] .

  Consensus-based Statement 2.S5
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Irradiation of the uterus can lead to uterine and tubal sterility and to increased pregnancy risks such as preterm birth, miscarriage and lower birth weight of the infant.

#### 2.3.4  Radiation damage to the hypothalamic/hypophyseal axis

  Consensus-based Recommendation 2.R4
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Before undergoing radiotherapy of the head region, patients must be informed about the risk of damaging the hypothalamic/hypophyseal axis and the consequences of this damage.

### 2.4  Gonadal toxicity through immunotherapy or targeted therapies

  Consensus-based Recommendation 2.R5
  ----------------------------------------------------------------------------------------------------------------------------------------------
  Women receiving therapy with bevacizumab should be informed about the risk of ovarian insufficiency and about methods to preserve fertility.

  Consensus-based Recommendation 2.R2
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients who receive immunotherapy or targeted therapy should be informed about the unclear risk of ovarian insufficiency and about methods to preserve fertility.

### 2.5  Gonadal toxicity from endocrine therapies

  Consensus-based Statement 2.S6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Data on gonadal toxicity of tamoxifen are limited and inconsistent; there are no data on the possible effects of aromatase inhibitors combined with GnRH agonists. A gonadotoxic effect is unlikely.

  Consensus-based Statement 2.S7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The most important fertility-reducing effect of endocrine therapy used to treat breast cancer is the length of the treatment, as it postpones the time when the patient can have children to a stage in life when patient has reduced ovarian reserve.

  Consensus-based Recommendation 2.R7
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ways of protecting fertility such as cryopreservation of fertilized and/or unfertilized oocytes or ovarian tissue should be discussed with women receiving endocrine therapy alone (5 -- 10 years) to treat breast cancer.

  Consensus-based Recommendation 2.R8
  ---------------------------------------------------------------------------------------------------------------------------------------------------
  The possibility of postponing or interrupting endocrine therapy may be discussed with the patient if this would allow her to have children early.

4  Methods of Fertility Protection for Girls and Women
------------------------------------------------------

( [Figs. 1](#FI6115549-1){ref-type="fig"} and [2](#FI6115549-2){ref-type="fig"} )

![ Flow diagram of potential approaches to protect the fertility of girls and women after the onset of menarche before they start gonadotoxic therapy.](10-1055-a-0611-5549-i6115549gf01){#FI6115549-1}

![ Fertility protection for women based on oncologic therapy and the available timeframe (modified from [@R6115549-1] ).](10-1055-a-0611-5549-i6115549gf02){#FI6115549-2}

### 4.1  Organ-preserving surgery

There are a number of S3 guidelines on the treatment of patients with malignant ovarian tumors, cervical cancer und endometrial cancer. To prevent discrepancies between guidelines, the guideline coordinators of the S3 guidelines and the coordinators of the S2k guideline on fertility preservation unanimously agreed to incorporate the relevant Statements, Recommendations and background texts from the S3 guidelines into the S2k guideline. The relevant Recommendations and Statements are available in the long version of the guideline.

### 4.2  Ovariopexy and gonadal protection for radiotherapy

  Consensus-based Statement 4.S25
  --------------------------------------------------------------------------------------------------------------------------------
  Transposition of the ovaries out of the area which will be irradiated may reduce the risk of radiogenic ovarian insufficiency.

  Consensus-based Recommendation 4.R33
  --------------------------------------------------------------------------------------------------------------------------------------------------------
  The possibility of an ovariopexy to preserve ovarian function must be discussed before commencing radiotherapy/radiochemotherapy of the lesser pelvis.

  Consensus-based Statement 4.S36
  ----------------------------------------------------------------------------------------------------
  If ovariopexy is performed, ovarian tissue may be harvested at the same time for cryopreservation.

### 4.3  GnRH agonists

  Consensus-based Statement 4.S47
  --------------------------------------------------------------------------------------------------------------------------------
  The data is still contradictory, so administering GnRH agonists as the only method for fertility protection is not sufficient.

  Consensus-based Statement 4.S58
  -----------------------------------------------------------------------------------------------------------------------------------
  Because of the contradictory study results, it is currently not possible to evaluate the benefit of administering a GnRH agonist.

  Consensus-based Recommendation 4.R34
  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Depending on the underlying tumor entity, GnRH agonists may be offered as a fertility protection measure if the patient has been informed in detail.

### 4.4  Cryopreservation of fertilized or unfertilized oocytes

  Consensus-based Statement 4.S19
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cryopreservation of fertilized and unfertilized oocytes is an established technique in reproductive medicine which can be used before starting gonadotoxic therapy.

#### 4.4.1  Controlled ovarian stimulation to harvest oocytes in cancer patients

  Consensus-based Statement 4.S20
  ------------------------------------------------------------------------------------------------------------------------------------------------------
  A protocol with the lowest possible risk of ovarian hyperstimulation syndrome should be used for ovarian stimulation treatment to protect fertility.

#### 4.4.2  Cryopreservation of unfertilized oocytes

( [Table 6](#TB6115549-6){ref-type="table"} )

###### 

**Table 6**  Outcomes for unfertilized oocytes after slow freezing or vitrification (modified from [@R6115549-8] and [@R6115549-9] ).

                                                                              Slow freezing   Vitrification
  --------------------------------------------------------------------------- --------------- -------------------
  Survival rate per unfertilized oocyte after cryopreservation/thawing        45 -- 67%       80 -- 90%
  Fertilization rate per unfertilized oocyte after cryopreservation/thawing   54 -- 68%       76 -- 83%
  Clinical pregnancy rate/transfers                                           11.6%           44.9% (p = 0.002)
  Congenital malformation rate                                                0.5%            1.3%

  Consensus-based Statement 4.S21
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In contrast to the cryopreservation of fertilized oocytes, the cryopreservation of unfertilized oocytes is not associated with a significantly increased rate of malformations or developmental deficits in children.

#### 4.4.3  Cryopreservation of fertilized oocytes

( [Tables 7](#TB6115549-7){ref-type="table"} and [8](#TB6115549-8){ref-type="table"} )

###### 

**Table 7**  Survival rate and development of embryos after slow freezing or vitrification (open/closed) (modified from [@R6115549-10] ).

                                                                                           Slow freezing   Vitrification (open/closed)
  ---------------------------------------------------------------------------------------- --------------- -----------------------------
  Survival rate per embryo after cryopreservation/thawing                                  63.8%           89.4%\*/87.6%\*
  Rate of intact morphology of all blastomeres per embryo after cryopreservation/thawing   44.3%           80.1%\*/76.1%\*

###### 

**Table 8**  Pregnancy outcomes for blastocysts after slow freezing or vitrification (modified from [@R6115549-11] and [@R6115549-8] ).

                                                                 Slow freezing   Vitrification
  -------------------------------------------------------------- --------------- ---------------
  Rate of transferred blastocysts per cryopreservation/thawing   71.4%           84.5%\*
  Rate of clinical pregnancies per transferred blastocyst        23.8%           32.7%\*\*
  Rate of live births per transferred blastocyst                 17.7%           24.8%\*\*\*

  Consensus-based Recommendation 4.R35
  ---------------------------------------------------------------------------------------------------------------
  The cryopreservation of unfertilized oocytes must be additionally offered, even if the patient has a partner.

### 4.5  Cryopreservation of ovarian tissue

  Consensus-based Statement 4.S22
  ------------------------------------------------------------------------------------------------------------------------
  Cryopreservation of ovarian tissue is an established method to restore fertility after receiving treatment for cancer.

  Consensus-based Statement 4.S23
  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Cryopreservation of ovarian tissue may be carried out at any time of the menstrual cycle and does not lead to any relevant delay in oncologic therapy.

#### 4.5.1  Harvesting and transport of ovarian tissue

  Consensus-based Recommendation 4.R36
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The harvested tissue must be cooled (4 -- 8 °C) during its transportation to a center which specializes in cryopreservation. The harvested tissue must be processed promptly, at the very latest 24 hours after harvesting.

#### 4.5.2  Cryopreservation of harvested tissue

Slow freezing is currently recommended for the cryopreservation of ovarian tissue because of the higher efficacy of this method in routine clinical practice [@R6115549-12] ,  [@R6115549-13] ,  [@R6115549-14] .

#### 4.5.3  Transplantation of tissue

  Consensus-based Recommendation 4.R37
  -----------------------------------------------------------------------------------------------------------------------------------
  Ovarian tissue must be transplanted orthotopically, i.e. on or into the ovary or close to the ovary in the retroperitoneal space.

  Consensus-based Recommendation 4.R38
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The patientʼs fertility (tubal, uterine and extrauterine factors) must be assessed when transplanting ovarian tissue and, if possible, corrections must carried out where necessary.

#### 4.5.4  Risk of tumor or disease recurrence after retransplantation

( [Table 9](#TB6115549-9){ref-type="table"} )

###### 

**Table 9**  Risk of ovarian metastasis for various tumor types (modified from Dolmans et al. [@R6115549-14] and Bastings et al. [@R6115549-15] ).

  High risk                                               Moderate risk                                                                                                                                          Low risk
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------
  leukemianeuroblastomaBurkittʼs lymphomaovarian tumors   stage IV breast cancer (lobular subtypes)bowel cancerendometrial carcinomagastric cancercervical adenocarcinomanon-Hodgkinʼs lymphomaEwingʼs sarcoma   stage I -- III breast cancer (ductal subtypes)cervical squamous cell carcinomaHodgkinʼs lymphomaosteosarcomanon-genital rhabdomyosarcomaWilmsʼ tumor

  Consensus-based Statement 4.S24
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of ovarian metastasis cannot be excluded for any type of tumor. To date, an increased risk has been found for leukemia, neuroblastoma, Burkittʼs lymphoma and malignant ovarian tumors.

  Consensus-based Recommendation 4.R39
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The patient must be informed before harvesting the tissue about the possible risk of transferring malignant cells by transplanting the harvested ovarian tissue.

### 4.6  Fertility-preserving or fertility-creating/fertility-restoring methods following uterine radiotherapy

  Consensus-based Recommendation 4.R40
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  If the patient wishes to have children, the dose administered to the uterus must be kept as low as possible using the latest radiation planning and techniques.

### 4.7  Combinations of fertility-protecting methods

  Consensus-based Recommendation 4.R41
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The patient must be offered combinations of different fertility-preserving methods (e.g. cryopreservation of oocytes, cryopreservation of ovarian tissue and/or the administration of GnRH agonists) to improve the efficacy of fertility protection methods.

6  Recommendations for Selected Tumor Entities in Women
-------------------------------------------------------

### 6.1  Breast cancer

#### 6.1.1  Fertility protection counseling for women with breast cancer

  Consensus-based Recommendation 6.R3
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Every fertile woman with breast cancer who might wish to have children must receive counseling about ovarian toxicity and the available methods to protect fertility before starting any potentially gonadotoxic therapy.

  Consensus-based Recommendation 6.R4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with metastatic breast cancer must receive individualized information on fertility protection which must also take account of the prognosis of a more limited life expectancy.

#### 6.1.2  Pregnancy after breast cancer

  Consensus-based Statement 6.S36
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  According to retrospective observational studies, pregnancy after treatment for breast cancer is not associated with a poorer prognosis with regard to the underlying disease.

#### 6.1.3  Limited fertility due to chemotherapy for breast cancer

The standard chemotherapy protocols to treat breast cancer in young women are anthracycline- and taxane-based chemotherapies. The rule of thumb for persistent amenorrhea following anthracycline-taxane-based regimens is estimated to be 10 -- 20% for women aged \< 30 years, while the rate of persistent amenorrhea for women aged more than 30 years ranges from 13 -- 68%, depending on the patientʼs age [@R6115549-16] ,  [@R6115549-17] .

#### 6.1.4  Limited fertility due to radiotherapy

  Consensus-based Statement 6.S32
  ----------------------------------------------------------------------------------------
  Regional radiotherapy to treat breast cancer is not associated with reduced fertility.

#### 6.1.5  Special aspects of fertility protection for women with hormone receptor-positive breast cancer, limited fertility due to endocrine therapy

  Consensus-based Recommendation 6.R55
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  If the patient has been carefully informed about the potential risks, pausing anti-tumor endocrine therapy (after a minimum of 2 years of therapy) may be considered to allow the patient to have children, after which the patient would resume therapy.

#### 6.1.6  Potential fertility protection methods for patients with breast cancer

( [Table 10](#TB6115549-10){ref-type="table"} )

###### 

**Table 10**  Retrospective studies on methods of cryopreservation in women with breast cancer.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                  Study                          Number of women   Methods                                                                                                                   Country
  ---------------------------------------- ------------------------------ ----------------- ------------------------------------------------------------------------------------------------------------------------- -------------
  Lawrenz et al., 2012 [@R6115549-18]      retrospective, single center   n = 56            ovarian tissue cryopreservation, GnRHa, hormone stimulation and cryopreservation of oocytes, combinations also possible   Germany

  Turan et al., 2013 [@R6115549-19]        retrospective cohort study\    n = 78            hormone stimulation and cryopreservation of oocytes                                                                       USA
                                           single center                                                                                                                                                              

  Sigismondi et al., 2015 [@R6115549-20]   retrospective, single center   n = 31            ovarian tissue cryopreservation, hormone stimulation and cryopreservation of oocytes                                      Italy

  Takae et al., 2015 [@R6115549-21]        retrospective, single center   n = 27            combination of ovarian tissue cryopreservation and hormone stimulation with cryopreservation of oocytes                   Japan

  Dahhan et al., 2015 [@R6115549-22]       retrospective, single center   n = 16            hormone stimulation and cryopreservation of oocytes                                                                       Netherlands

  Oktay et al., 2015 [@R6115549-23]        retrospective, single center   n = 131           hormone stimulation with/without letrozole and cryopreservation of oocytes                                                USA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Consensus-based Statement 6.S33
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Irrespective of the patientʼs hormone status, there are no conclusive data about the potential impact of hormone stimulation for oocyte retrieval before starting planned neoadjuvant systemic therapy for breast cancer on the patientʼs oncologic prognosis.

  Consensus-based Recommendation 6.R56
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hormone stimulation for oocyte retrieval can be done in patients with hormone receptor-positive breast cancer receiving concomitant anti-hormone treatment (e.g. aromatase inhibitors or tamoxifen).

#### 6.1.7  GnRH agonists (GnRHa) for women with breast cancer

A recent systematic meta-analysis about the use of GnRHa in women with breast cancer [@R6115549-26] evaluated the data from 1962 women, 541 of whom received chemotherapy without GnRHa and 521 of whom were treated with chemotherapy and GnRHa [@R6115549-26] . The rate of spontaneous menstruation recurrence after completing chemotherapy was higher in the group treated with concomitant GnRHa (OR: 2.57; 95% CI: 1.65 -- 4.01; p \< 0.0001). However, there was no significant difference in pregnancy rates between the two groups. Another recent meta-analysis (n = 1231, [@R6115549-27] ) found a significantly reduced risk of premature ovarian insufficiency (OR: 0.36; 95% CI: 0.41 -- 0.73, p \< 0.001) for patients who received concomitant GnRHa during chemotherapy, together with a slightly but significantly increased pregnancy rate (OR: 1.83; 95% CI: 1.02 -- 3.28; p = 0.041).

#### 6.1.8  Reduced ovarian reserve in women with BRCA1 mutation

Comparative studies have pointed out that women with BRCA1 mutation may have reduced ovarian reserve compared to healthy women [@R6115549-24] ,  [@R6115549-25] .

### 6.2  Ovarian/borderline tumors

#### 6.2.1  Borderline tumors

  Consensus-based Recommendation 6.R57
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After women who have had fertility-preserving surgery to treat an ovarian/borderline tumor and who wish to have children have been informed about the potential risks involved, physicians may consider offering hormone stimulation to them as part of fertility treatment.

  Consensus-based Recommendation 6.R58
  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Before undergoing bilateral salpingo-oophorectomy, women should be offered the possibility of cryopreserving unfertilized and fertilized oocytes.

  Consensus-based Recommendation 6.R59
  -------------------------------------------------------
  Cryopreservation of ovarian tissue may be considered.

#### 6.2.2  Ovarian cancer

  Consensus-based Statement 6.S34
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fertility treatment is possible in patients with early ovarian cancer (FIGO Ia, G1/G2) who were treated using a fertility-preserving approach and were given detailed information about the risks.

### 6.3  Solid tumors

#### 6.3.1  Sarcomas

  Consensus-based Recommendation 6.R60
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Every fertile woman with sarcoma who may wish to have a child must be informed about the ovarian toxicity of treatment and the methods of preserving fertility before starting a potentially gonadotoxic therapy.

  Consensus-based Statement 6.S35
  --------------------------------------------------------------------------------------------------------
  There are no indications that pregnancy after treatment for sarcoma will result in a poorer prognosis.

  Consensus-based Statement 6.S36
  ------------------------------------------------------------------------------------------------------------------------------------------
  Depending on the patientʼs age, chemotherapy to treat osteosarcoma and soft tissue sarcoma will result in primary ovarian insufficiency.

  Consensus-based Recommendation 6.R61
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with sarcoma should be offered cryopreservation of ovarian tissue to protect fertility. The risk of recurrence caused by transplantation of the tissue cannot be excluded and must be discussed with the patient before harvesting ovarian tissue.

  Consensus-based Recommendation 6.R62
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty, patients with sarcoma should be informed about the possibility of cryopreserving oocytes, if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R63
  -----------------------------------------------------------------------------------------
  A GnRH agonist can be administered to patients with sarcoma during gonadotoxic therapy.

#### 6.3.2  Colorectal cancer

  Consensus-based Recommendation 6.R64
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Every fertile woman with colorectal cancer who may wish to have a child must be informed about the ovarian toxicity of treatment and methods of preserving fertility before starting a potentially gonadotoxic therapy.

  Consensus-based Statement 6.S37
  ---------------------------------------------------------------------------------------------------------------
  According to case reports, pregnancy after rectal cancer is not associated with a poorer oncologic prognosis.

  Consensus-based Statement 6.S38
  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemotherapeutic treatment of colorectal cancer with 5-fluorouracil, folinic acid and oxaliplatin is reported to have a low risk of ovarian insufficiency.

  Consensus-based Recommendation 6.R65
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with colorectal cancer should be offered cryopreservation of ovarian tissue to protect fertility. The risk of disease recurrence caused by transplantation cannot be excluded and must be discussed with the patient before harvesting ovarian tissue.

  Consensus-based Recommendation 6.R66
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty, patients with colorectal cancer should be informed about the possibility of cryopreserving oocytes if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R67
  ---------------------------------------------------------------------------------------------------
  A GnRH agonist can be administered to patients with colorectal cancer during gonadotoxic therapy.

### 6.4  Hematologic disease

#### 6.4.1  Lymphomas (Hodgkinʼs and non-Hodgkinʼs lymphoma)

  Consensus-based Statement 6.S39
  ------------------------------------------------------------------------------------------------------
  With lymphomas, the risk of primary ovarian insufficiency depends on the chemotherapy protocol used.

  Consensus-based Recommendation 6.R68
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cryopreservation of ovarian tissue to protect fertility must be offered to patients with lymphoma who are expected to have a high risk of premature ovarian insufficiency from oncologic therapy. The risk of ovarian metastasis is low for Hodgkinʼs lymphoma and high for non-Hodgkinʼs lymphoma and Burkittʼs lymphoma.

  Consensus-based Recommendation 6.R69
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty, patients with lymphoma should be informed about the possibility of cryopreserving oocytes if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R70
  ----------------------------------------------------------------------------------------------------------------------------------------------
  A GnRH agonist can be administered to patients with lymphoma during gonadotoxic therapy. This can help prevent thrombocytopenic menorrhagia.

#### 6.4.2  Leukemia

##### 6.4.2.1  Acute lymphatic leukemia (ALL)

  Consensus-based Statement 6.S40
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of infertility after treatment for ALL depends on the protocol used for treatment. Women who were treated with a conditioning protocol to prepare them for stem cell transplantation have a high risk of infertility. Patients treated with a conventional protocol have a low risk of infertility.

  Consensus-based Statement 6.S41
  --------------------------------------------------------------------------------------------------------------------------------------------
  Depending on the dose, cranial irradiation during treatment for ALL can lead to treatable impairment of the hypothalamic-hypophyseal axis.

  Consensus-based Recommendation 6.R71
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with ALL who have a high risk of POI from therapy and who cannot postpone their gonadotoxic therapy can be offered the option of cryopreserving ovarian tissue to protect their fertility.

  Consensus-based Recommendation 6.R72
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of tumor recurrence after autotransplantation of ovarian tissue is considered to be high in patients with ALL, and autotransplantation is therefore not recommended.

  Consensus-based Recommendation 6.R73
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty, patients with ALL should be informed about the possibility of cryopreserving oocytes if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R74
  -----------------------------------------------------------------------------------------------------------------------------------------
  A GnRH agonist can be administered to patients with ALL during gonadotoxic therapy. This can help prevent thrombocytopenic menorrhagia.

##### 6.4.2.2  Acute myeloid leukemia (AML)

  Consensus-based Statement 6.S42
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of infertility after treatment for AML depends on the protocol used for treatment. Women treated with a conditioning protocol to prepare them for stem cell transplantation have a high risk of infertility. Patients treated with a conventional protocol have a low risk of infertility.

  Consensus-based Recommendation 6.R75
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients with AML who have a high risk of POI from therapy and who cannot postpone their gonadotoxic therapy can be offered the option of cryopreserving ovarian tissue to protect their fertility.

  Consensus-based Recommendation 6.R76
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of tumor recurrence after autotransplantation of ovarian tissue is considered to be high in patients with AML, and autotransplantation is therefore not recommended.

  Consensus-based Recommendation 6.R77
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty, patients with AML should be informed about the possibility of cryopreserving oocytes if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R78
  -----------------------------------------------------------------------------------------------------------------------------------------
  A GnRH agonist can be administered to patients with AML during gonadotoxic therapy. This can help prevent thrombocytopenic menorrhagia.

##### 6.4.2.3  Chronic myelogenous leukemia (CML)

  Consensus-based Statement 6.S43
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of ovarian insufficiency following the administration of tyrosine kinase inhibitors (TKI) is unclear, with TKI reported to have a teratogenic potential.

  Consensus-based Recommendation 6.R79
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The risk of disease recurrence after autotransplantation of ovarian tissue is considered to be high in patients with CML, and autotransplantation is therefore not recommended.

##### 6.4.2.4  Stem cell transplantation

  Consensus-based Recommendation 6.R80
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Women treated with a conditioning protocol to prepare them for stem cell transplantation have a high risk of infertility. These patients must be informed and receive counseling about methods to protect their fertility.

  Consensus-based Recommendation 6.R81
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After the onset of puberty and before starting conditioning for stem cell transplantation, patients should be informed about the possibility of cryopreserving oocytes if the start of oncologic therapy can be postponed by at least 2 weeks.

  Consensus-based Recommendation 6.R82
  ---------------------------------------------------------------------------------------------------------------------------------------
  Patients can be offered the option of cryopreserving ovarian tissue to protect fertility before undergoing stem cell transplantation.

8  Malignant Disease in Children and Adolescents
------------------------------------------------

In addition to the established methods to protect fertility before and after treatment for malignant disease mainly targeting post-pubertal boys and girls, experimental methods are also available, particularly for prepubertal children. Listed below are instructions concerning the use of fertility protection methods which need to be taken into account before starting therapy.

  Consensus-based Recommendation 8.R92
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The efficacy of administering drugs for fertility protection (e.g. a GnRH agonist) in childhood or early adolescence is still questionable. GnRH agonists must not be administered to prepubertal patients.

  Consensus-based Recommendation 8.R93
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Depending on the expected radiation dose administered to the ovary, the possibility of ovariopexy must be discussed during the tumor conference. The recommendation for ovariopexy must be discussed with the patient and her family.

  Consensus-based Recommendation 8.R94
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After puberty patients can undergo stimulation treatment to cryopreserve oocytes. This must be done before starting treatment for malignant disease if cancer therapy can be postponed by 2 weeks.

  Consensus-based Recommendation 8.R95
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  It is currently not clear what the indications for cryopreserving ovarian tissue from prepubertal and peripubertal girls are. The decision for or against cryopreservation requires the type of therapy and the gonadotoxic dose to be weighed up in each individual case.

  Consensus-based Recommendation 8.R96
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  After puberty, potential options for fertility preservation include cryopreserving sperm (ejaculation, electrostimulation, testicular biopsy with testicular sperm extraction \[TESE\]) and cryopreserving testicular tissue as a fertility reserve for assisted reproduction techniques to be used at a later date. The patient and his family must be informed about these options.

  Consensus-based Statement 8.S48
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The cryopreservation of immature testicular tissue extracted by biopsy before the onset of puberty is still in its experimental stages. The subsequent maturation of sperm from spermatogonial stem cells, which would be necessary for this approach, is currently not yet possible in humans. Transplanting cryopreserved tissue always carries the risk of transplanting malignant cells.

9  Psychological and Ethical Aspects of Fertility Preservation
--------------------------------------------------------------

  Consensus-based Statement 9.S49
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  All patients of reproductive age with malignant disease and children with malignant disease and their parents should be offered counseling and advice on fertility protection using a biopsychosocial framework. Information about the options for and the limits of fertility protection should be made available to affected patients both orally and in writing (e.g., in the form of publications like "Die Blauen Ratgeber" -- a German series of publications issued by the German Cancer Society) through low-threshold publications which enable patients to make their decisions based on informed consent.

  Consensus-based Statement 9.S50
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  During open-ended counseling, the different options and perspectives available must be presented and discussed without bias or preference: oncologic therapy without fertility protection, oncologic therapy after fertility protection measures, and pregnancy, childbirth and starting a family must be discussed in ways that take account of different healing processes and courses of disease.

Appendix to the Guideline
=========================

A standard operating procedure (SOP) on managing the contact with a patient before the patient starts oncologic treatment which will reduce their fertility while the patient may still want to have children is included in the appendix of the long (German) version of the guideline, together with leaflets on preserving fertility which were compiled together with the German Cancer Society (DKG).
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ABVD

:   Docorubicin, Bleomyccin, Vinblastin, Dacarbazin

AC

:   Doxorubicin, Cyclophosphamid

ALL

:   akute lymphatische Leukämie

AMH

:   Anti-Müller-Hormon

AML

:   akute myeloplastische Leukämie

ART

:   Assisted Reproductive Technologies

BEACOPP

:   Bleomycin, Etoposid, Doxorubicin, Cyclophophamid, Vincristin, Procarbazin, Prednison

BOT

:   Borderlinetumor

CAF

:   Cyclophosphamid, Adriamycin, Fluorouracil

CEF

:   Cyclophosphamid, Epirubicin, 5-Flourouracil

ChlVPP/EVA hybrid COPP

:   Chlorambucil, Vinblastin, Procarbazin, Prednison/ Etoposid, Vincristin, Doxorubicin

CHOP

:   Cyclophosphamid, Doxorubicin, Vincristin, Prednisolon

CMF

:   Cyclophosphamid, Methotrexat, 5-Fluorouracil

CML

:   chronische myeloische Leukämie

CVP

:   Cyclophosphamid, Vincristin, Prednison

DMSO

:   Dimethylsulfoxid

EC

:   Epirubicin, Cyclophosphamid

ESD

:   effektive sterilisierende Dosis

FOLFOX

:   Folinsäure (Leucovorin), 5-Fluorouracil, Oxaliplatin

GnRH

:   Gonadotropin-releasing-Hormon

GnRHa

:   Gonadotropin-releasing-Hormon-Agonisten

Gy

:   Gray

HL

:   Hodgkin-Lymphom

KI

:   Konfidenzintervall

MVPP

:   Mustin, Vinblastin, Procarbazin, Prednisolon

NHL

:   Non-Hodgkin-Lymphom

OR

:   Odds Ratio

POI

:   prämature Ovarialinsuffizienz

RR

:   relatives Risiko

SZT

:   Stammzelltransplantation

TAC

:   Paclitaxel (Taxol), Doxorubicin (Adriamycin), Cyclophosphamid  

II  Leitlinienverwendung
========================

Fragestellung und Ziele
=======================

Die Zielorientierung der Leitlinie beinhaltet Handlungsempfehlung für die Beratung und Anwendung von fertilitätserhaltenden Maßnahmen bei Präpubertären und Patienten/-innen im reproduktiven Alter unter Berücksichtigung ihrer Lebensumstände und ihres Risikoprofils. Hierdurch soll die Erfüllung des Kinderwunsches nach überstandener onkologischer Therapie und die Lebensqualität der Patienten/-innen erhöht werden.

Versorgungsbereich
==================

-   ambulanter Versorgungssektor

-   stationärer Versorgungssektor

-   teilstationäre Versorgungssektoren

Patienten/innen-Zielgruppe
==========================

Die Leitlinie richtet sich an alle Präpubertären und Patienten/-innen im reproduktiven Alter, die sich aufgrund einer malignen Erkrankung einer gonadotoxischen Behandlung unterziehen müssen.

Anwenderzielgruppe/Adressaten
=============================

Diese Leitlinie richtet sich an alle Ärzte und Angehörige von Berufsgruppen, die mit der Versorgung von Patientinnen und Patienten, die einer gonadotoxischen Therapie bedürfen, befasst sind.

Hier sind vor allem zu nennen: Gynäkologen, Reproduktionsmediziner, Andrologen, Urologen, Onkologen, Radioonkologen, Allgemeinmediziner, Pädiater, Pathologen, Psychoonkologen.

Verabschiedung und Gültigkeitsdauer
===================================

Diese Leitlinie besitzt eine Gültigkeitsdauer vom 01.11.2017 bis 31.10.2020. Diese Dauer ist aufgrund der inhaltlichen Zusammenhänge geschätzt. Bei wichtigen Änderungen der Evidenz werden auch vor dem Ablauf dieser Frist Ergänzungen (Amendments) der Leitlinie nach methodischer Absicherung über die AWMF publiziert.

III  Methodik
=============

Grundlagen
==========

Die Methodik zur Erstellung dieser Leitlinie wird durch die Vergabe der Stufenklassifikation vorgegeben. Das AWMF-Regelwerk (Version 1.0) gibt entsprechende Regelungen vor. Es wird zwischen der niedrigsten Stufe (S1), der mittleren Stufe (S2) und der höchsten Stufe (S3) unterschieden. Die niedrigste Klasse definiert sich durch eine Zusammenstellung von Handlungsempfehlungen, erstellt durch eine nicht repräsentative Expertengruppe. Im Jahr 2004 wurde die Stufe S2 in die systematische evidenzrecherchebasierte (S2e) oder strukturelle konsensbasierte Unterstufe (S2k) gegliedert. In der höchsten Stufe S3 vereinigen sich beide Verfahren.

Diese Leitlinie entspricht der Stufe: S2k

Empfehlungsgraduierung
======================

Während mit der Darlegung der Qualität der Evidenz (Evidenzstärke) die Belastbarkeit der publizierten Daten und damit das Ausmaß an Sicherheit/Unsicherheit des Wissens ausgedrückt wird, ist die Darlegung der Empfehlungsgrade Ausdruck des Ergebnisses der Abwägung erwünschter und unerwünschter Konsequenzen alternativer Vorgehensweisen.

Die Evidenzgraduierung und Empfehlungsgraduierung einer Leitlinie auf S2k-Niveau ist nicht vorgesehen. Es werden die einzelnen Empfehlungen nur sprachlich -- nicht symbolisch -- unterschieden. Die gewählte Formulierung des Empfehlungsgrades sollte im Hintergrundtext erläutert werden ( [Tab. 2](#TB6115549DE-2){ref-type="table"} ).

###### 

**Tab. 2**  Graduierung von Empfehlungen.

  Beschreibung der Verbindlichkeit                    Ausdruck
  --------------------------------------------------- ---------------------
  starke Empfehlung mit hoher Verbindlichkeit         soll/soll nicht
  einfache Empfehlung mit mittlerer Verbindlichkeit   sollte/sollte nicht
  offene Empfehlung mit geringer Verbindlichkeit      kann/kann nicht

Statements
==========

Sollten fachliche Aussagen nicht als Handlungsempfehlungen, sondern als einfache Darlegung Bestandteil dieser Leitlinie sein, werden diese als „Statements" bezeichnet. Bei diesen Statements ist die Angabe von Evidenzgraden nicht möglich.

Konsensusfindung und Konsensusstärke
====================================

Im Rahmen einer strukturellen Konsensusfindung (S2k/S3-Niveau) stimmen die berechtigten Teilnehmer der Sitzung die ausformulierten Statements und Empfehlungen ab. Hierbei kann es zu signifikanten Änderungen von Formulierungen etc. kommen. Abschließend wird abhängig von der Anzahl der Teilnehmer eine Stärke des Konsensus ermittelt ( [Tab. 3](#TB6115549DE-3){ref-type="table"} ).

###### 

**Tab. 3**  Einteilung zur Zustimmung der Konsensusbildung.

  Symbolik   Konsensusstärke            prozentuale Übereinstimmung
  ---------- -------------------------- --------------------------------------------
  +++        starker Konsens            Zustimmung von \> 95% der Teilnehmer
  ++         Konsens                    Zustimmung von \> 75 -- 95% der Teilnehmer
  \+         mehrheitliche Zustimmung   Zustimmung von \> 50 -- 75% der Teilnehmer
  --         kein Konsens               Zustimmung von \< 50% der Teilnehmer

Expertenkonsens
===============

Wie der Name bereits ausdrückt, sind hier Konsensusentscheidungen speziell für Empfehlungen/Statements ohne vorige systemische Literaturrecherche (S2k) oder aufgrund von fehlender Evidenzen (S2e/S3) gemeint. Der zu benutzende Expertenkonsens (EK) ist gleichbedeutend mit den Begrifflichkeiten aus anderen Leitlinien wie „Good Clinical Practice" (GCP) oder „klinischer Konsensuspunkt" (KKP). Die Empfehlungsstärke graduiert sich gleichermaßen wie bereits im Kapitel Empfehlungsgraduierung beschrieben ohne die Benutzung der aufgezeigten Symbolik, sondern rein semantisch („soll"/„soll nicht" bzw. „sollte"/„sollte nicht" oder „kann"/„kann nicht").

IV  Leitlinie
=============

Im Folgenden werden die Statements und Empfehlungen für Mädchen und Frauen dargestellt.

1  Einleitung in die Thematik Fertilitätsprotektion bei onkologischen Erkrankungen
==================================================================================

1.2  Bedeutung und Problematik der Fertilitätsprotektion bei Krebs
==================================================================

Onkologische Therapien führen häufig zu einer partiellen oder kompletten Schädigung der Gonadenfunktion bei beiden Geschlechtern mit dem möglichen Einhergehen eines Verlustes der Keimzellen. Unter dem Eindruck einer lebensbedrohenden Erkrankung scheint für Nichtbetroffene die Thematik der späteren Fruchtbarkeit unbedeutend. Für viele Patienten/-innen selbst stellt jedoch die vorzeitige ovarielle Insuffizienz oder die Zeugungsunfähigkeit sowohl für die Betroffenen als auch für ihre Partner eine sehr belastende Situation dar [@R6115549-2] ,  [@R6115549-3] .

  Konsensbasierte Empfehlung 1.E1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Einschätzung des Risikos einer möglichen Unfruchtbarkeit und die Auswahl der Methode(n) des Fertilitätserhaltes sollen interdisziplinär und rechtzeitig vor der onkologischen Therapie mit dem/der Patienten/-in besprochen werden.

  Konsensbasiertes Statement 1.S1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Beratung über Konzepte zum Erhalt der Fertilität soll unter Berücksichtigung der Lebensumstände, der empfohlenen onkologischen Therapien und des individuellen Risikoprofils ein integraler Bestandteil onkologischer Behandlungen von Patientinnen und Patienten sein.

2  Ursachen der Gonadotoxizität bei Frauen
==========================================

2.1  Schädigungen der Gonaden durch die operative Therapie
==========================================================

Je nach Radikalität der operativen Maßnahme kommt es bei gynäkologisch onkologischen Erkrankungen durch komplette oder teilweise Entfernung des Uterus und/oder der Ovarien zur Sterilität. Auf das fertilitätserhaltende operative Vorgehen wird bei den einzelnen Tumorentitäten im Kapitel 4.1 der Langversion der Leitlinie eingegangen.

2.2  Gonadotoxizität durch Chemotherapie
========================================

Die gonadale Toxizität der einzelnen Chemotherapeutika hängt von deren Wirkmechanismus, der Dosierung, der Therapiedauer, der Applikationsform, der Begleitbehandlung wie eine simultane Radiotherapie oder eine ovardestruierende Operation, dem Alter der Patientin und der individuellen Disposition ab ( [Tab. 4](#TB6115549DE-4){ref-type="table"} ).

###### 

**Tab. 4**  Ovartoxische Wirkung verschiedener Chemotherapeutika (modifiziert nach [@R6115549-4] ,  [@R6115549-5] ).

  Risiko                                                                      Regime/Substanz
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hohes Risiko (\> 80%iges Risiko für eine permanente Amenorrhö)              CMF, CEF, CAF, TAC × 6 bei Frauen ≥ 40 JahreKonditionierung für Stammzelltransplantation (insbesondere alkylanzienbasierte myeloablative Konditionierung mit Busulfan, Cyclophosphamid, Melphalan)BEACOPP × 6 -- 8 bei Frauen \> 35 Jahre
  intermediäres Risiko (40 -- 60%iges Risiko für eine permanente Amenorrhö)   CMF, CEF, CAF, TAC × 6 bei Frauen 30 -- 39 JahreAC × 4 bei Frauen ≥ 40 JahreAC oder EC × 4 → TaxanBEACOPP × 6 -- 8 bei Frauen 25 -- 35 JahreCHOP × 6 bei Frauen ≥ 35 Jahreknochen- und weichteilsarkomtypische Therapie
  niedriges Risiko (\< 20%iges Risiko für eine permanente Amenorrhö)          CMF, CEF, CAF, TAC × 6 bei Frauen ≤ 30 JahreAC × 4 bei Frauen ≤ 40 JahreBEACOPP × 6 -- 8 bei Frauen \< 25 JahreABVD × 2 -- 4CHOP × 6 bei Frauen \< 35 JahreCVPAML-typische Therapie (Anthrazyklin/ Cytarabin)ALL-typische Therapie (multi-agent)FOLFOX bei Frauen ≤ 40 Jahre
  sehr niedriges oder kein Risiko für eine permanente Amenorrhö               MethotrexatFluorouracilVincristin

  Konsensbasiertes Statement 2.E2
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Frauen, die Chemotherapeutika mit potenziell gonadotoxischer Dosis erhalten, sollen über das Risiko einer Ovarialinsuffizienz und fertilitätserhaltende Maßnahmen aufgeklärt werden.

  Konsensbasiertes Statement 2.S3
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die negative Auswirkung der Gonadentoxizität von Chemotherapien steigt mit dem Alter der Patientin an. Nicht alle Patienten einer Altersgruppe mit einem definierten Therapieschema entwickeln die gleiche Fertilitätsstörung.

2.3  Gonadotoxizität durch Strahlentherapie
===========================================

2.4  Gonadotoxizität durch Immuntherapie oder zielgerichtete Therapien
======================================================================

  Konsensbasierte Empfehlung 2.E5
  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Frauen, die eine Therapie mit Bevacizumab erhalten, sollten über das Risiko einer Ovarialinsuffizienz und fertilitätserhaltende Maßnahmen aufgeklärt werden.

  Konsensbasierte Empfehlung 2.E2
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patientinnen, die Immuntherapien oder zielgerichtete Therapien erhalten, sollten über das unklare Risiko einer Ovarialinsuffizienz und fertilitätserhaltende Maßnahmen aufgeklärt werden.

2.5  Gonadotoxizität durch endokrine Therapien
==============================================

  Konsensbasiertes Statement 2.S6
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Zur Gonadotoxizität von Tamoxifen liegen begrenzte und inkonsistente Daten vor, zu möglichen Effekten von Aromatasehemmern in Kombination mit GnRH-Agonisten liegen keine Daten vor. Eine gonadotoxische Wirkung ist nicht wahrscheinlich.

  Konsensbasiertes Statement 2.S7
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Der wichtigste fertilitätsmindernde Einfluss einer endokrinen Therapie beim Mammakarzinom besteht in der Dauer der Behandlung, welche die Erfüllung des Kinderwunsches in eine Lebensphase mit reduzierter ovarieller Reserve verschiebt.

  Konsensbasierte Empfehlung 2.E7
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bei einer alleinigen endokrinen Therapie (5 -- 10 Jahre) des Mammakarzinoms sollten fertilitätsprotektive Maßnahmen wie Kryokonservierung von fertilisierten und/oder unfertilisierten Oozyten bzw. Ovargewebe diskutiert werden.

  Konsensbasierte Empfehlung 2.E8
  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Verschiebung oder Unterbrechung einer endokrinen Therapie kann diskutiert werden, um eine frühzeitige Verwirklichung des Kinderwunsches zu ermöglichen.

4  Methoden der Fertilitätsprotektion bei Mädchen und Frauen
============================================================

( [Abb. 1](#FI6115549DE-1){ref-type="fig"} und [2](#FI6115549DE-2){ref-type="fig"} )

![ Flussdiagramm zum allgemeinen Vorgehen bei Fertilitätserhaltung vor einer gonadotoxischen Therapie bei postmenarchalen Mädchen und Frauen.](10-1055-a-0611-5549-i6115549gfde01){#FI6115549DE-1}

![ Fertilitätsprotektive Maßnahmen für Frauen in Abhängigkeit von der onkologischen Therapie und dem verfügbaren Zeitfenster (modifiziert nach [@R6115549-1] ).](10-1055-a-0611-5549-i6115549gfde02){#FI6115549DE-2}

4.1  Organerhaltende Operationsverfahren
========================================

Für die Behandlung von Patientinnen mit malignen Ovarialtumoren, Zervixkarzinomen und Endometriumkarzinomen existieren S3-Leitlinien. Um keine Diskrepanzen zwischen den Leitlinien zu haben, wurde zwischen den Leitlinienkoordinatoren der S3-Leitlinien und den Koordinatoren der S2k-Leitlinie Fertilitätserhalt übereinstimmend beschlossen, die entsprechenden Statements, Empfehlungen und Hintergrundtexte aus den S3-Leitlinien in die S2k-Leitlinie zu übernehmen. Die entsprechenden Empfehlungen und Statements können der Langversion der Leitlinie entnommen werden.

4.2  Ovariopexie und Gonadenschutz bei Bestrahlung
==================================================

  Konsensbasiertes Statement 4.S25
  ------------------------------------------------------------------------------------------------------------------------------
  Durch Transposition der Ovarien aus dem Bestrahlungsfeld kann das Risiko für radiogene Ovarialinsuffizienz reduziert werden.

  Konsensbasierte Empfehlung 4.E33
  ------------------------------------------------------------------------------------------------------------------------------------------
  Bei einer Radiatio/Radiochemotherapie des kleinen Beckens soll eine Ovariopexie zur Erhaltung der ovariellen Funktion diskutiert werden.

  Konsensbasiertes Statement 4.S36
  ----------------------------------------------------------------------------------------------------------
  Bei einer Ovariopexie kann eine gleichzeitige Entnahme von Ovarialgewebe zur Kryokonservierung erfolgen.

4.3  GnRH-Agonisten
===================

  Konsensbasiertes Statement 4.S47
  ----------------------------------------------------------------------------------------------------------------------------------
  GnRH-Agonisten sind als alleinige Option zur Fertilitätsprotektion aufgrund der widersprüchlichen Studienlage nicht ausreichend.

  Konsensbasiertes Statement 4.S58
  ------------------------------------------------------------------------------------------------------------------------
  Der Nutzen einer GnRH-Agonisten-Gabe kann derzeit aufgrund widersprüchlicher Studienergebnisse nicht beurteilt werden.

  Konsensbasierte Empfehlung 4.E34
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GnRH-Agonisten können als fertilitätsprotektive Maßnahme nach ausführlicher Aufklärung in Abhängigkeit von der zugrunde liegenden Tumorentität angeboten werden.

4.4  Kryokonservierung von fertilisierten oder unfertilisierten Oozyten
=======================================================================

  Konsensbasiertes Statement 4.S19
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Kryokonservierung von befruchteten und unbefruchteten Eizellen sind etablierte, reproduktionsmedizinische Techniken, die vor einer gonadotoxischen Therapie angewendet werden können.

4.5  Kryokonservierung von Ovarialgewebe
========================================

  Konsensbasiertes Statement 4.S22
  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Die Kryokonservierung von Ovarialgewebe ist eine etablierte Methode, um die Fertilität nach der Behandlung der Krebserkrankung wiederherzustellen.

  Konsensbasiertes Statement 4.S23
  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Kryokonservierung von ovariellem Gewebe kann unabhängig vom Zyklus erfolgen und führt zu keiner relevanten Verzögerung der onkologischen Therapie.

4.6  Fertilitätserhaltende oder fertilitäts(wieder)herstellende Maßnahmen bei Uterusbestrahlung
===============================================================================================

  Konsensbasierte Empfehlung 4.E40
  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Bei bestehendem Kinderwunsch soll die Dosis am Uterus durch moderne Bestrahlungsplanung und -techniken so gering wie irgend möglich gehalten werden.

4.7  Kombination fertilitätsprotektiver Maßnahmen
=================================================

  Konsensbasierte Empfehlung 4.E41
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Kombination verschiedener fertilitätserhaltender Maßnahmen (z. B. der Kryokonservierung von Eizellen, Kryokonservierung von Ovarialgewebe und/oder der Gabe von GnRH-Agonisten) zur Steigerung der Effektivität soll der Patientin angeboten werden.

6  Empfehlungen zu ausgewählten Tumorentitäten bei Frauen
=========================================================

6.1  Mammakarzinom
==================

6.2  Ovarial-/Borderlinetumoren
===============================

6.3  Solide Tumoren
===================

6.4  Hämatologische Erkrankungen
================================

8  Maligne Erkrankungen im Kindes- und Jugendalter
==================================================

Neben etablierten fertilitätsprotektiven Maßnahmen vor und nach Therapie, insbesondere für postpubertäre Jungen und Mädchen, stehen auch experimentelle Maßnahmen, insbesondere bei präpubertären Kindern, zur Verfügung. Folgend aufgelistet sind zu beachtende Hinweise zur Anwendung fertilitätsprotektiver Maßnahmen vor Therapie:

  Konsensbasierte Empfehlung 8.E92
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Wirksamkeit einer medikamentösen Protektion (z. B. GnRH-Agonisten) im Jugendalter ist bislang noch fraglich. Vor der Pubertät soll eine GnRH-Agonisten-Behandlung nicht stattfinden.

  Konsensbasierte Empfehlung 8.E93
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Ovariopexie soll in Abhängigkeit von der zu erwartenden Strahlendosis am Ovar in der Tumorkonferenz besprochen werden. Die Empfehlung soll mit der Patientin und der Familie besprochen werden.

  Konsensbasierte Empfehlung 8.E94
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Postpubertär kann nach Stimulationsbehandlung eine Kryokonservierung von Oozyten erfolgen. Dies soll vor Therapiebeginn stattfinden, wenn dieser um 2 Wochen verschoben werden kann.

  Konsensbasierte Empfehlung 8.E95
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Indikation zur Kryokonservierung von Ovarialgewebe bei prä- und peripubertären Mädchen ist derzeit unklar. Sie erfordert eine individuelle Abwägung von der Art der Therapie und der gonadotoxischen Dosis.

  Konsensbasierte Empfehlung 8.E96
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Eine Kryokonservierung von Spermien nach der Pubertät (Ejakulation, Elektrostimulation, Hodenbiopsie mit testikulärer Spermienextraktion \[TESE\]) sowie die Kryokonservierung von Hodengewebe als Fertilitätsreserve für spätere Maßnahmen der assistierten Reproduktion sind möglich. Der Patient und die Familie sollen über diese Optionen aufgeklärt werden.

  Konsensbasiertes Statement 8.S48
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Die Kryokonservierung von immaturem Hodengewebe vor der Pubertät, welches mittels Biopsie entnommen wird, ist noch ein experimenteller Ansatz. Die erforderliche, anschließende Spermienreifung aus den spermatogonialen Stammzellen ist beim Menschen aktuell noch nicht möglich. Bei Transplantation des kryokonservierten Gewebes besteht die Gefahr der Transplantation von malignen Zellen.

9  Psychologische und ethische Aspekte des Fertilitätserhalts
=============================================================

  Konsensbasiertes Statement 9.S49
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Allen von einer Krebserkrankung betroffenen Patientinnen/Patienten im reproduktiven Alter, Kindern sowie deren Eltern sollte möglichst frühzeitig eine Beratung zur Fertilitätsprotektion auf bio-psychosozialer Grundlage angeboten werden. Informationen zu den Möglichkeiten und den Grenzen der Fertilitätsprotektion sollte den betroffenen Patientinnen und Patienten mündlich und schriftlich (z. B. „Die blauen Ratgeber") niedrigschwellig zur Verfügung gestellt werden, um eine Entscheidungsfindung im Sinne einer „informed consent" zu ermöglichen.

  Konsensbasiertes Statement 9.S50
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  In der ergebnisoffenen Beratung sollen die verschiedenen Optionen und Perspektiven gleichwertig thematisiert werden: onkologische Therapie ohne Fertilitätsprotektion, onkologische Therapie nach fertilitätserhaltenden Maßnahmen, sowie Schwangerschaft, Kindsgeburt und Familiengründung auf dem Hintergrund unterschiedlicher Heilungs- bzw. Krankheitsverläufe.

Anhang in der Leitlinie
=======================

Im Anhang der Langversion der Leitlinie befinden sich ein standardisiertes Vorgehen (SOP) bei Kontakt mit einer Patientin/einem Patienten vor einer fertilitätsreduzierenden Therapie und nicht abgeschlossener Familienplanung sowie Aufklärungsbögen über Fertilitätserhalt zur Verfügung, die zusammen mit der Deutschen Krebsgesellschaft erstellt wurde.
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